Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.
暂无分享,去创建一个
C. Rowe | R. Martins | C. Masters | P. Maruff | D. Ames | S. Burnham | V. Villemagne | K. Ellis | A. Rembach | J. Doecke | S. Macaulay | A. Watt | A. Bush | William J. Wilson
[1] H. Kiiveri,et al. A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study , 2014, Molecular Psychiatry.
[2] Kingshuk Roy Choudhury,et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. , 2013, Radiology.
[3] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[4] Olivier Salvado,et al. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.
[5] Deborah Blacker,et al. Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. , 2012, Archives of neurology.
[6] Dong Han,et al. Diagnostic accuracy of 18F‐FDG and 11C‐PIB‐PET for prediction of short‐term conversion to Alzheimer’s disease in subjects with mild cognitive impairment , 2012, International journal of clinical practice.
[7] Guanghua Xiao,et al. A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI , 2011, PloS one.
[8] Miles C. Miller,et al. Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent , 2011, Fluids and Barriers of the CNS.
[9] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[10] C. Jack,et al. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid , 2011, Alzheimer's & Dementia.
[11] Todd E. Golde,et al. Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.
[12] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[13] Mark A Mintun,et al. Relationship of dementia screening tests with biomarkers of Alzheimer's disease. , 2010, Brain : a journal of neurology.
[14] Miles C. Miller,et al. Amyloid Efflux Transporter Expression at the Blood-Brain Barrier Declines in Normal Aging , 2010, Journal of neuropathology and experimental neurology.
[15] F. Verhey,et al. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. , 2010, Current Alzheimer research.
[16] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[17] Miles C. Miller,et al. Amyloid Deposition and Influx Transporter Expression at the Blood-Brain Barrier Increase in Normal Aging , 2010, Journal of neuropathology and experimental neurology.
[18] Denise C. Park,et al. Beta-Amyloid Deposition and the Aging Brain , 2009, Neuropsychology Review.
[19] C. Rowe,et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.
[20] A. Fagan,et al. Biomarkers of Alzheimer's disease , 2009, Neurobiology of Disease.
[21] R. Tibshirani,et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.
[22] A. Fagan,et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.
[23] R. Petersen,et al. Cognitive measures predict pathologic Alzheimer disease. , 2006, Archives of neurology.
[24] G. Ratcliff,et al. Preclinical Alzheimer disease , 2004, Neurology.
[25] P. Mehta,et al. Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease , 2001, Neuroscience Letters.
[26] N. Inestrosa,et al. Platelets Are the Primary Source of Amyloid β-Peptide in Human Blood , 1995 .
[27] D. Selkoe,et al. Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.
[28] A. Monsch,et al. Neuropsychological signs of Alzheimer's disease 8 years prior to diagnosis. , 2013, Journal of Alzheimer's disease : JAD.
[29] R. Mayeux,et al. Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.